WO1994006909A3 - Procede de prevention de metastase tumorale - Google Patents

Procede de prevention de metastase tumorale Download PDF

Info

Publication number
WO1994006909A3
WO1994006909A3 PCT/US1993/008531 US9308531W WO9406909A3 WO 1994006909 A3 WO1994006909 A3 WO 1994006909A3 US 9308531 W US9308531 W US 9308531W WO 9406909 A3 WO9406909 A3 WO 9406909A3
Authority
WO
WIPO (PCT)
Prior art keywords
met
hgf
antibody
substance
preventing tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1993/008531
Other languages
English (en)
Other versions
WO1994006909A2 (fr
Inventor
Donna L. Faletto
Ilan Tsarfaty
Sing Rong
Marianne Oskarsson
George F. Vande Woude
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to DE69315440T priority Critical patent/DE69315440T2/de
Priority to JP50817794A priority patent/JP3553936B2/ja
Priority to DK93921471T priority patent/DK0662130T3/da
Priority to EP93921471A priority patent/EP0662130B1/fr
Priority to AU48555/93A priority patent/AU675968B2/en
Publication of WO1994006909A2 publication Critical patent/WO1994006909A2/fr
Publication of WO1994006909A3 publication Critical patent/WO1994006909A3/fr
Anticipated expiration legal-status Critical
Priority to GR980400340T priority patent/GR3026165T3/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

Procédé de prévention de métastase de cellule tumorale au moyen de l'inhibition de la liaison du facteur de croissance d'hépatocyte/facteur de dispersion ('HGF/SF') avec la protéine proto-oncogène met. Un procédé de production d'HGF/SF et une lignée cellulaire permettant de produire HGF/SF sont également décrits.
PCT/US1993/008531 1992-09-18 1993-09-15 Procede de prevention de metastase tumorale Ceased WO1994006909A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE69315440T DE69315440T2 (de) 1992-09-18 1993-09-15 Eine Methode zur Herstellung von Hepatozytwachstumsfaktor und eine Zelllinie
JP50817794A JP3553936B2 (ja) 1992-09-18 1993-09-15 Ｈｇｆ／ｓｆの生産およびそれに有用な細胞系
DK93921471T DK0662130T3 (da) 1992-09-18 1993-09-15 Fremgangsmåde til fremstilling af hepatocytvækstfaktor og en cellelinje
EP93921471A EP0662130B1 (fr) 1992-09-18 1993-09-15 Méthode pour la préparation du facteur de croissance d'hépatocytes et une ligne céllulaire
AU48555/93A AU675968B2 (en) 1992-09-18 1993-09-15 A method of preventing tumor metastasis
GR980400340T GR3026165T3 (en) 1992-09-18 1998-02-18 A method of preventing tumor metastasis.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94606192A 1992-09-18 1992-09-18
US07/946,061 1992-09-18

Publications (2)

Publication Number Publication Date
WO1994006909A2 WO1994006909A2 (fr) 1994-03-31
WO1994006909A3 true WO1994006909A3 (fr) 1994-05-26

Family

ID=25483898

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/008531 Ceased WO1994006909A2 (fr) 1992-09-18 1993-09-15 Procede de prevention de metastase tumorale

Country Status (10)

Country Link
EP (2) EP0805203B1 (fr)
JP (2) JP3553936B2 (fr)
AT (2) ATE160585T1 (fr)
AU (1) AU675968B2 (fr)
CA (1) CA2144856A1 (fr)
DE (2) DE69334159D1 (fr)
DK (1) DK0662130T3 (fr)
ES (1) ES2112997T3 (fr)
GR (1) GR3026165T3 (fr)
WO (1) WO1994006909A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9487589B2 (en) 2011-06-30 2016-11-08 Genentech, Inc. Anti-c-met-antibody formulations

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344321B1 (en) * 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US6566098B1 (en) 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
CA2144081C (fr) * 1992-09-16 2004-11-30 Filip Roos Protection contre les lesions du foie au moyen du hgf
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6855685B2 (en) 1995-10-24 2005-02-15 Toshikazu Nakamura Anti-cancer agent
JP3832674B2 (ja) * 1995-10-24 2006-10-11 敏一 中村 抗癌剤
WO1998019696A1 (fr) * 1996-11-05 1998-05-14 Smithkline Beecham Corporation Antagonistes du facteur de croissance hepatocytaire
AU1465400A (en) * 1998-11-04 2000-05-22 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Identification of inhibitors of the hgf-met-upa-plasmin network using a novel cellular assay
IL131142A0 (en) * 1999-07-28 2001-01-28 Rad Ramot Prognosis of breast cancer and other diseases
WO2001034650A1 (fr) * 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Combinaison d'anticorps monoclonaux hgf-sf
AU2001277854B2 (en) * 2000-06-29 2007-03-01 North Shore-Long Island Jewish Health System Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
BRPI0407446A (pt) * 2003-02-13 2006-01-31 Pharmacia Corp Anticorpos para c-met para o tratamento de cânceres
TWI476206B (zh) 2003-07-18 2015-03-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CA2575402A1 (fr) 2004-08-05 2006-02-09 Genentech, Inc. Antagonistes anti-cmet humanises
EP1863519B1 (fr) 2005-03-31 2013-09-25 The General Hospital Corporation Modulation de hgf/hgfr pour traiter un lymphoedème
CN101193910A (zh) 2005-04-15 2008-06-04 健泰科生物技术公司 HGFβ链变体
US8133867B2 (en) 2006-03-20 2012-03-13 Seikagaku Corporation Method for treating rheumatoid arthritis with an antibody that binds to a hepatocyte growth factor receptor
US8101727B2 (en) 2006-03-30 2012-01-24 Novartis Ag Compositions and methods of use for antibodies of c-Met
PT3904391T (pt) 2010-03-10 2024-10-14 Genmab As Anticorpos monoclonais contra c-met
RU2608644C2 (ru) 2010-11-03 2017-01-23 арДЖЕН-ИКС Н.В. Антитела против белка рецептора с-мет
AU2012240424B2 (en) 2011-04-02 2017-10-26 Washington State University Hepatocyte growth factor mimics as therapeutic agents
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
ES2748295T3 (es) 2014-09-16 2020-03-16 Symphogen As Anticuerpos anti-MET y composiciones

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0456188A1 (fr) * 1990-05-09 1991-11-13 Toshikazu Nakamura Médicament contre la cirrhose du foie
WO1992005184A1 (fr) * 1990-09-14 1992-04-02 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Antagoniste de facteur de croissance d'hepatocytes competitif non mitogene
WO1992013097A1 (fr) * 1991-01-18 1992-08-06 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Proto-oncogene met recepteur du facteur de croissance hepatique
WO1993015754A1 (fr) * 1992-02-06 1993-08-19 United States Of America, As Represented By The Secretary Of Health And Human Services Recepteur du facteur de croissance hepatique

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9003621D0 (en) * 1990-02-16 1990-04-11 Imp Cancer Res Tech Protein factor
ATE222603T1 (de) * 1992-05-18 2002-09-15 Genentech Inc Hepatozytwachstumfaktor variante

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0456188A1 (fr) * 1990-05-09 1991-11-13 Toshikazu Nakamura Médicament contre la cirrhose du foie
WO1992005184A1 (fr) * 1990-09-14 1992-04-02 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Antagoniste de facteur de croissance d'hepatocytes competitif non mitogene
WO1992013097A1 (fr) * 1991-01-18 1992-08-06 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Proto-oncogene met recepteur du facteur de croissance hepatique
WO1993015754A1 (fr) * 1992-02-06 1993-08-19 United States Of America, As Represented By The Secretary Of Health And Human Services Recepteur du facteur de croissance hepatique

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
D.G. BLAIR ET AL.: "New method for detecting cellular transforming genes", SCIENCE, vol. 218, 10 December 1982 (1982-12-10), AAAS, WASHINGTON, DC, US;, pages 1122 - 1125 *
N. SHIMA ET AL.: "Tumor cytotoxic factor/Hepatocyte growth factor from human fibroblasts: Cloning of its cDNA, purification and characterization of recombinant protein", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 180, no. 2, 31 October 1991 (1991-10-31), ACADEMIC PRESS, N.Y., US;, pages 1151 - 1158, XP000230641, DOI: doi:10.1016/S0006-291X(05)81187-8 *
N.A. LOKKER ET AL.: "Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding", EMBO JOURNAL, vol. 11, no. 7, July 1992 (1992-07-01), IRL PRESS LIM., OXFORD, ENGL.;, pages 2503 - 2510, XP002036379 *
S. RONG ET AL.: "Tumorigenesis induced by coexpression of human hepatocyte growth factor and the human met protooncogene leads to high levels of expression of the ligand and the receptor", CELL GROWTH & DIFFERENTIATION, vol. 4, no. 7, July 1993 (1993-07-01), WAVERLY PRESS, INC., BALTIMORE,MD,US;, pages 563 - 569, XP000674468 *
S. RONG ET AL.: "Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor", MOL. CELL. BIOL., vol. 12, no. 11, November 1992 (1992-11-01), AM. SOC. MICROBIOL., WASHINGTON, D.C. US;, pages 5152 - 5158, XP000674463 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9487589B2 (en) 2011-06-30 2016-11-08 Genentech, Inc. Anti-c-met-antibody formulations

Also Published As

Publication number Publication date
JPH08504093A (ja) 1996-05-07
EP0662130B1 (fr) 1997-11-26
ES2112997T3 (es) 1998-04-16
DK0662130T3 (da) 1998-08-10
WO1994006909A2 (fr) 1994-03-31
DE69315440T2 (de) 1998-07-09
JP3553936B2 (ja) 2004-08-11
JP2004002440A (ja) 2004-01-08
CA2144856A1 (fr) 1994-03-31
EP0805203B1 (fr) 2007-08-01
DE69334159D1 (de) 2007-09-13
AU675968B2 (en) 1997-02-27
DE69315440D1 (de) 1998-01-08
EP0662130A1 (fr) 1995-07-12
AU4855593A (en) 1994-04-12
ATE160585T1 (de) 1997-12-15
ATE368738T1 (de) 2007-08-15
GR3026165T3 (en) 1998-05-29
EP0805203A1 (fr) 1997-11-05

Similar Documents

Publication Publication Date Title
WO1994006909A3 (fr) Procede de prevention de metastase tumorale
NO2017038I2 (no) Adalimumab - Forlenget SPC
DE69433406D1 (de) Antikörper gegen cd40
EP0765172A4 (fr) Anticorps monoclonaux croises se liant specifiquement a la selectine e et a la selectine p
EP1314431A3 (fr) Virus de la maladie de newcastle pour les utilisations thérapeutiques
BG101024A (bg) Моноклонално антитяло срещу сd44v6
EP0820769A3 (fr) Utilistaion de benzotiophénes pour la fabrication d'un médicament pour le traitement de maladies associées à un exés de tachykinines
PL328858A1 (en) Immunogenous peptides
US5262555B1 (en) Method for the preparation of acryloxy group-containing or methacryloxy group-containing organosilicon compounds
GR3034447T3 (en) Lectin domain variants of selectin.
GB9009106D0 (en) Processes and intermediates for synthetic antibody derivatives
IL143516A (en) E3 ubiquitin ligase polypeptide, polynucleotide encoding the same and uses thereof
DE69301904D1 (de) Zusammensetzung zur behandlung von keratinfasern
FI961380A7 (fi) Koostumuksia virusten aiheuttamien kasvainten ehkäisemiseksi ja hoitam iseksi
FI922551A0 (fi) Foerfarande foer skoetsel av septisk chock.
GR76280B (fr)
DE69302287D1 (de) Erniedrigung des Benzolgehaltes von Benzinen durch Isomerisierung
FR2699369B1 (fr) Couvercle pour canister cryobiologique.
CA2145005A1 (fr) Anticorps monoclonal specifique pour le tcf-ii
AU6309690A (en) Stabilization of monoclonal antibody for use in fluorescent polarization techniques
EP0642803A3 (fr) Fermeture pour Tracheostomie.
GR3017920T3 (en) Bcrf1 antagonists for treating epstein-barr virus infections.
Kerimov et al. Electric magnetic and interference corrections of the second Born approximation for the cross section of elastic electron scattering by nuclei
Kuznetsov et al. The behaviour of strontium and cesium radioisotopes with colloidal compounds of iron and manganese; Povedenie radioizotopov strontsiya i tseziya s kolloidnymi soedineniyami zheleza i margantsa
IT1126301B (it) Chiusura anti svitamento,particolarmente per bottiglie,flaconi e simili,contenente sostanze nocive

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2144856

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1993921471

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993921471

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1993921471

Country of ref document: EP